OMB 0651-0031

OF COMMERCE l number.

A-69566-1/RFT/RMS/RMK

Please type a plus sign (+) inside this box — Under the Paperwork Reduction Act of 1995, no person are required to rest	U.S. Patent and Tra	PTG Approved for use through 10/31/2002. demark Office: U.S. DEPARTMENT n unless it contains a valid OMB contro
		Complete if Known
Substitute for form 1449A/PTO	Application Number	09/903,378
INFORMATION DISCLOSURE	Filing Date	July 10, 2001
STATEMENT BY APPLICANT	First Named Inventor	CHIRINO, Arthur J.
STATEMENT BY MY DICKY	Group Art Unit	1645
(use as many sheets as necessary)	Examiner Name	

Sheet	1		of	5		Attorney I	Docket Number	A-69566-	1/RFT/RMS/RMK	
					U.S. PATE	ENT DOCU	JMENTS			96
Examiner	Cite No.1	U.S. Patent I	Document		Name of Patentee or	Applicant	Date of Publicate Cited Docume	ion of	Pages, Columns, Where Relev	L ines , ant
Initials*	No.	Number	Kind Co	de² wn)	of Cited Docu	ıment	MM-DD-YY	YY	Passages or Rel Figures Appe	evant ear
MS	Al	6,269,312		Bì	MAYO et al.		07-31-2001			
	-						 			
	-			_						
	+-						 			
	+			-						
	ļ									
	<u> </u>									
				_						
	+-			-						
	+									
			-							

Attorney Docket Number

						FOREIGN PATENT DOCUMEN	NTS		
Examiner Initials*	Cite No.1					Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
ms	B1	EP	0 752 886		B1	M&E BIOTECH A/S	01-1997		4
/ //	B2	WO	98/52976		Al	BIOVATION LTD	11-1998		—
	В3	wo	98/47089		A1	CALIF INST. TECHNOLOGY	10-1998		
	B4	wo	99/11777		A1	BIOVATION LTD	03-1999		-↓-
ners	B5	WO	00/34317		A3	BIOVATION LTD	06-2000		-
									-
	1								
		1 -							

Date Examiner Considered Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Please type a plus sign (+) inside this box

PTO/SB/8B (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

		V	3	U.S. Fatent and Trac	unless it contains a valid OMB control m	umber	
			reasons are recorred to respo	olid to a concentration of information	Complete if Known	_ 오	
Substitute for form 1449B/PTO				Application Number	09/903,378	<u> </u>	Į.
TNIT7	ODMATIO	N DI	SCLOSURE	Filing Date	July 10, 2001	<u> </u>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Named Inventor	CHIRINO, Arthur J.	<u></u>	~
SIA	ALEMENT	DI A	HILICANI	Group Art Unit	1645		_
	(use as many sh	eets as	necessary)	Examiner Name			_ <u>_</u>
Sheet	T 2	of	5	Attorney Docket Number	A-69566-1/RFT/RMS/RMK		
Sheet		<u> </u>			O CLIP CENTRO		

Sneet			<u> </u>
		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), muhlisher city and/or country where published.	Т
	C1	ABRAMS, S.I. and SCHLOM, J., "Rational antigen modification as a strategy to upregulate or downregulate antigen	
MN	C2	recognition," Curr Opin Immunol. 2000 Feb;12(1):85-91 ALTUVIA, Y. et al., "A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets." Hum Immunol. 1997 Nov;58(1):1-11	
	C3	ANDERTON, S.M. et al., "Therapeutic potential of TCR antagonists is determined by their ability to medicate a	
_	C4	BOESTEANU, A. et al., "A molecular basis for how a single TCR interfaces multiple ligands, a himman and a single TCR interfaces multiple ligands, a himman and a single TCR interfaces multiple ligands, a himman and a single TCR interfaces multiple ligands, a himman and a single TCR interfaces multiple ligands, a himman and a single TCR interfaces multiple ligands, a himman and a single TCR interfaces multiple ligands, a himman and a single TCR interfaces multiple ligands, a himman and a single TCR interfaces multiple ligands, a himman and a single TCR interfaces multiple ligands, a himman and a single TCR interfaces multiple ligands, a himman and a single TCR interfaces multiple ligands, a himman and a single TCR interfaces multiple ligands, a himman and a single TCR interfaces multiple ligands, and a single TCR interfaces multiple ligands	v
	C5	1;161(9):4719-27 BOWIE, J.U. et al., "A method to identify protein sequences that fold into a known three-dimensional structure." Science. 1991 Jul 12;253(5016):164-70	
	C6	BRUSIC, V., et al., "MHCPEP, a database of MHC-binding peptides: update 1997, Nucleic Actus Ness. 1996 state	
_	C7	1;26(1):368-71 BRUSIC, V., et al. "Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network." <i>Bioinformatics</i> . 1998;14(2):121-30	1
	C8	BUTTINELLI, G., et al., "Antigenic sites of poliovirus type 3 eliciting IgA monocional antibodics in Grany	
	C9	BUUS, S. "Description and prediction of peptide-MHC binding: the human MHC project." Curr opin immunos	
	C10	1999 Apr;11(2):209-13 CHICZ, R.M. et al., "Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size," <i>Nature</i> . 1992 Aug 27;358(6389):764-8	
	C11	CORREIA-NEVES, M. et al., "Amino acids specifying MHC class preference in TCR v alpha 2 regions"	
	C12		
	C13	17.100(4) 1705 0	
	C14	17.00	;
	C15	C deconontide library." Fur I Riochem. 1996 Aug 13,240(1).71-7	
	C16	FREMONT, D.H., et al. "Crystal structures of two viral peptides in complex with murine with class 111 272,	
	C17		
nn	CI	1: the affinite complex class II-behild interaction but a	

l		рериче ман то			
١	Examiner Signature	Wom	Date Considered	84/03	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF-QOMMERCE
ellection of information unless it contains a valid OMB control full ber. Under the Paperwork Reduction Act of 1995, no Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	(use as many	5770015 015		
Sheet	3	of	5	

	Complete if Known	T AUTHORI		工
Application Number	09/903,378	CE	Š	
Filing Date	July 10, 2001	3	ربر <u>دی</u>	1
First Named Inventor	CHIRINO, Arthur J.		ත	
Group Art Unit	1645	<u>ත</u>	20	_≰
Examiner Name		<u> </u>	02	┚
Attorney Docket Number	A-69566-1/RFT/RMS/RMK	8		
		Õ		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
item (book, magazine, journal, serial, symposum, catalog, etc.), date, page(s), volunte-issue infinitions, item (book, magazine, journal, serial, symposum, catalog, etc.), date, page(s), volunte-issue infinitions, item (book, magazine, journal, symposum, catalog, etc.), date, page(s), volunte-issue infinitions, item (book, magazine, journal, symposum, catalog, etc.), date, page(s), volunte-issue infinitions, item (book, magazine, journal, symposum, catalog, etc.), date, page(s), volunte-issue infinitions, item (book, magazine, journal, symposum, catalog, etc.), date, page(s), volunte-issue infinitions, item (book), and (book),	\perp		
1	C20	HAMMER, J. "New methods to predict MHC-binding sequences within protein antigens." Curr Opin Immunol. 1993	
	C21	HAMMER, J. et al., "Rules governing peptide-class II MHC molecule interactions." <i>Behring Inst Mitt.</i> 1994	
	C22	HARBURY, P.B. et al., "Repacking protein cores with backbone freedom: structure prediction for coiled coils." <i>Proc</i>	
	C23	HELLINGA, H.W. and RICHARDS, F.M. "Optimal sequence selection in proteins of known structure by simulated explication." Proc. Natl. Acad. Sci. U.S.A., 1994. Jun 21:91(13):5803-7	_
	C24	HEMMER, B. et al., "Predictable TCR antigen recognition based on peptide scans leads to the identification of exempt ligands with no sequence homology," <i>J. Immunol.</i> 1998 Apr 15;160(8):3631-6	
	C25	HIEMSTRA, H.S. et al., "Antigen arrays in T cell immunology." Curr Opin Immunol. 2000 Feb;12(1):80-4	1
	C26		4
	C27	Oct: 16(10):966-9	1
	C28	Apr 3/4):567-74	
	C29	KONO, H. and DOI, J. "Energy minimization method using automata network for sequence and side-chain conformation prediction from given backbone geometry." <i>Proteins</i> . 1994 Jul;19(3):244-55	_
	C30	LAM, K.S. et al., "A new type of synthetic peptide library for identifying ligand-binding activity," <i>Nature</i> . 1991 Nov	\perp
	C31	LAROCHE, Y. et al., "Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-	
_	C32	MADDEN, DR., "The three-dimensional structure of peptide-MHC complexes," Annu Rev Immunol. 1995;13:587-	
+	C33	MALCHEREK, G. et al., "Analysis of allele-specific contact sites of natural HLA-DR17 ligands," J Immunol. 1994	
	C34	MALLIOS, RR. "Iterative stepwise discriminant analysis: a meta-algorithm for detecting quantitative sequence	
-	C35	MALLIOS, RR. "Class II MHC quantitative binding motifs derived from a large molecular database with a versatile	
ms	C36	MARVIN, J.S. and HELLINGA, H.W., "Conversion of a maltose receptor into a zinc biosensor by computational design," <i>Proc Natl Acad Sci U S A</i> . 2001 Apr 24;98(9):4955-60	

Examiner Signature	Upm	Date Considered	04/03

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

PTO/SB/KE (08-00)
Approved for use through 10/31/2002. OME 651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

. 1 41 D		1005 n	nersons PAnnis AUN respo	U.S. Patent and Trad and to a collection of information	unless it contains a valid OMB control	number.	× ×
			o persons a continue to respe		Complete if Known	Z	_
Substitute for form 1449B/PTO				Application Number	09/903,378	<u> </u>	<u>~~</u>
INE	ORMATIO	v Di	SCLOSURE	Filing Date	July 10, 2001		<u>~</u>
STATEMENT BY APPLICANT				First Named Inventor	CHIRINO, Arthur J.	_8	001
SIA		<i>)</i>	ATT LICITIVE	Group Art Unit	1645	28	
	(use as many sh	eets as	necessary)	Examiner Name		<u>S</u>	
Sheet	4	of	5	Attorney Docket Number	A-69566-1/RFT/RMS/RMK		_

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
Examiner Initials*	Cite No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1
my	C37	MEISTER, G.E., et al., "Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences," <i>Vaccine</i> . 1995 Apr;13(6):581-91	
1	C38	MEYER, D.L. et al., "Reduced antibody response to streptavidin through site-directed mutagenesis," <i>Protein Sci.</i> 2001 Mar;10(3):491-503	1
	C39	FRAZER, J.K. and CAPRA, J.D., "Immunoglobiulins: Structure and Function." in Fundamental Immunology Fourth Edition, PAUL, W.E. (ed.), Lippincott-Raven Publishers, Philadelphia, 1999, Chapter 3, pp. 37-74	
	C40	MARGULIES, D.H., "The Major Histocompatibility Complex," in Fundamental Immunology Fourth Edition, PAUL, W.F. (ed.) Lippincoff-Rayen Publishers, Philadelphia, 1999, Chapter 8, pp. 263-285	
	C41	BENOIST, C. and MATHIS, D., "T-Lymphocyte Differentiation and Biology," in Fundamental Immunology Fourth Edition, PAUL, W.F. (ed.), Lippincott-Rayen Publishers, Philadelphia, 1999, Chapter 11, pp. 367-409	
	C42	PEREZ, M., "cDNA cloning and immunological characterization of the rye grass allergen Lol p I," <i>J Biol Chem.</i> 1990 Sep 25;265(27):16210-5	
	C43	RAMMENSEE, H. et al., "SYFPEITHI: database for MHC ligands and peptide motifs," <i>Immunogenetics</i> . 1999 Nov;50(3-4):213-9	
	C44	ROBERTS, C.G. et al., "Prediction of HIV peptide epitopes by a novel algorithm," AIDS Res Hum Retroviruses 1996 May 1,12(7):593-610	
	C45	RUDENSKY, A et al., "Sequence analysis of peptides bound to MHC class II molecules." <i>Nature</i> . 1991 Oct 17;353(6345):622-7	
	C46	SAROBE, P. et al., "Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions." <i>J Clin Invest.</i> 1998 Sep 15:102(6):1239-48	
	C47	SAVOIE, C.J. et al., "Use of BONSAI decision trees for the identification of potential MHC class I peptide epitope motifs." Pac Symp Biocomput. 1999;:182-9	
	C48	SCHWARTZ, H.L. et al., "High-resolution autoreactive epitope mapping and structural modeling of the 65 kDa form of human glutamic acid decarboxylase," <i>J Mol Biol.</i> 1999 Apr 16;287(5):983-99	
	C49	SETTE, A. et al., "Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II," <i>J Exp Med.</i> 1995 Feb 1;181(2):677-83	
1	C50	SHASTRI, N., "Single T cell probes for antigen/MHC expression," Curr Opin Immunol. 1995 Apr,7(2):258-62	
	C51	SHASTRI, N. "Needles in haystacks: identifying specific peptide antigens for T cells." Curr Opin Immunol. 1996 Apr;8(2):271-7	
	C52	SIDNEY, J. et al., "Measurement of MHC/Peptide Interactions by Gel Filtration," in Current Protocols in Immunology, Coligan, J.E. et al. (eds.), John Wiley and Sons (1998) 18.3.1-18.3.19	
m	C53		

			
Examiner Signature	Mins	Date Considered	04/03
			•

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Please type a plus sign	(+) inside this box	→[Ŧ
-------------------------	---------------------	-----

PTO/SB/8B (08-00)
Approved for use through 10/31/2002. OMB 065# 6031

Under the Pap	perwork Reduction Act of	1995, n	o person are required to respo	U.S. Patent and Trac	lemark Office: U.S. DEPARTMENT Of unless it contains a valid OMB control n	F COMMERCE	
Substitute for form 1449B/PTO					Complete if Known		Ē
24024	VAVO 191 191111 1 V V Z			Application Number	09/903,378		
INF	ORMATIO	N D	ISCLOSURE	Filing Date	July 10, 2001	<u> </u>	· `
STATEMENT BY APPLICANT				First Named Inventor	CHIRINO, Arthur J.	16	<u>۔</u>
~ 11				Group Art Unit	1645	00/	3
(use as many sheets as necessary)			necessary)	Examiner Name	•	290	_
Sheet	5	of	5	Attorney Docket Number	A-69566-1/RFT/RMS/RMK	8	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials* Cite item (book, magazine, journal, serial, publisher,		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Feb 1;181(2):449-51			
	C55	STURNIOLO, T. et al., "Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices," <i>Nat Biotechnol</i> . 1999 Jun;17(6):555-61	
	C56	THIMME, R. et al., "Degenerate immunogenicity of an HLA-A2-restricted hepatitis B virus nucleocapsid cytotoxic T-lymphocyte epitope that is also presented by HLA-B51," <i>J Virol</i> . 2001 Apr;75(8):3984-7	
	C57	TSUTSUMI, Y. et al., "Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity," <i>Proc Natl Acad Sci USA</i> . 2000 Jul 18;97(15):8548-53.	
	C58	UDAKA, K. et al., "Decrypting the structure of major histocompatibility complex class I-restricted cytotoxic T lymphocyte epitopes with complex peptide libraries." <i>J Exp Med.</i> 1995 Jun 1;181(6):2097-108	
	C59	VOGT, A.B. and KROPSHOFER, H. "HLA-DM - an endosomal and lysosomal chaperone for the immune system." Trends Biochem Sci. 1999 Apr;24(4):150-4	
	C60	WALDEN, P. et al., "Elucidation of T-cell epitopes: a synthetic approach with random peptide libraries." <i>Biochem Soc Trans.</i> 1995 Aug;23(3):678-81	
	C61	WALDEN, P. "T-cell epitope determination." Curr Opin Immunol. 1996 Feb;8(1):68-74	
nus	C62	WATTS, C., "Capture and processing of exogenous antigens for presentation on MHC molecules," Annu Rev Immunol. 1997;15:821-50	
			+
			+
	ļ		+
			+

Examiner Signature	llom	Date Considered	04/03
		-	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.